The efficacy of ONC-392 monotherapy in ovarian cancer sets the stage for this multicenter, open-label phase 2 combined immunotherapy clinical trial

ROCKVILLE, MD, USA, December 30, 2022 (GLOBE NEWSWIRE), OncoC4 Corporation today announced, In a Phase 2 combined immunotherapy trial of a new generation anti-CTLA-4 antibody, ONC-392, and Merck's anti-PD-1 antibody, KEYTRUDA® (pembrolizumab), in patients with platinum-resistant ovarian cancer (PROC) (Presert-004), NCT05446298) has been activated and the first patient has been successfully dosed.

The first patient received her first treatment at Women's Cancer Hospital in Albany, New York. Dr Joyce Barlin is the principal investigator (PI) at the centre. The Phase II clinical trial was sponsored by OncoC4 and developed in partnership with Merck (known as Merck in the United States and Canada) and the American Gynecological Cancer Foundation (GOG).

"Ovarian cancer immunotherapy clinical trial research is at an exciting stage. I am extremely honored to have the opportunity to co-lead this Phase 2 trial with Dr. Bradley Monk, "said Joyce Barlin, M.D.," We are very excited to infuse the first patient at our facility with this innovative combination immunotherapy, which has the potential to address the unmet clinical need for platinum-resistant ovarian cancer."

"The successful administration of ONC-392 in combination with KEYTRUDA in the first patient with ovarian cancer is an important milestone in the clinical development of ONC-392. We are very excited about the results as it builds on the promising results we have already seen with ONC-392 monotherapy in ovarian cancer, "said Pan Zheng, Ph.D., Chief Medical Officer and co-founder of OncoC4. "We are grateful to our partners Merck and the GOG Foundation for their support of the PRESERVE-004 trial," she added.

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.